Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C14H12O3S.C4H11NO3 |
| Molecular Weight | 381.443 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(CO)(CO)CO.CC(C(O)=O)C1=CC=C(S1)C(=O)C2=CC=CC=C2
InChI
InChIKey=PDWBZKWQZFGXGU-UHFFFAOYSA-N
InChI=1S/C14H12O3S.C4H11NO3/c1-9(14(16)17)11-7-8-12(18-11)13(15)10-5-3-2-4-6-10;5-4(1-6,2-7)3-8/h2-9H,1H3,(H,16,17);6-8H,1-3,5H2
Tiaprofenic acid is a non-steroidal, anti-inflammatory, analgesic compound, which nonselectively inhibits cyclooxygenase protein. Tiaprofenic acid was approved in Europe for the symptomatic relief of arthritis, ankylosing spondylitis and other inflammatory-rheumatic disorders as well as the painful conditions after injury.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094253 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | SURGAM Approved UseSymptomatic treatment of pain and inflammation in acute arthritis (including gout attack), chronic arthritis (rheumatoid arthritis in particular), ankylosing spondylitis and other inflammatory-rheumatic spinal disorders, irritation in degenerative joint and spine diseases (arthritis and spondylarthritis), inflammatory soft tissue rheumatic diseases, painful swelling or inflammation after injury. |
|||
| Primary | SURGAM Approved UseSymptomatic treatment of pain and inflammation in acute arthritis (including gout attack), chronic arthritis (rheumatoid arthritis in particular), ankylosing spondylitis and other inflammatory-rheumatic spinal disorders, irritation in degenerative joint and spine diseases (arthritis and spondylarthritis), inflammatory soft tissue rheumatic diseases, painful swelling or inflammation after injury. |
|||
| Palliative | SURGAM Approved UseSymptomatic treatment of pain and inflammation in acute arthritis (including gout attack), chronic arthritis (rheumatoid arthritis in particular), ankylosing spondylitis and other inflammatory-rheumatic spinal disorders, irritation in degenerative joint and spine diseases (arthritis and spondylarthritis), inflammatory soft tissue rheumatic diseases, painful swelling or inflammation after injury. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Reinduction of the hypnotic effects of thiopental with NSAIDs by decreasing thiopental plasma protein binding in humans. | 1993 Apr |
|
| Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis. | 1993 Apr |
|
| Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. | 1993 Jan |
|
| Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. | 2001 |
|
| Eotaxin expression and eosinophil infiltrate in the liver of patients with drug-induced liver disease. | 2001 Apr |
|
| Mechanism of lipid peroxidation photosensitized by tiaprofenic acid: product studies using linoleic acid and 1,4-cyclohexadienes as model substrates. | 2001 Apr |
|
| In vitro effects of NSAIDS and paracetamol on oxidative stress-related parameters of human erythrocytes. | 2001 Jun |
|
| Screening procedure for detection of non-steroidal anti-inflammatory drugs and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation. | 2001 May-Jun |
|
| Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients. | 2001 Nov |
|
| [Photoaggravated contact allergy and contact photoallergy caused by ketoprofen: 19 cases]. | 2001 Oct |
|
| The effect of flurbiprofen and tiaprofenic acid on serum cytokine levels of patients with osteoarthrosis. | 2001 Oct |
|
| Photocontact dermatitis to ketoprofen. | 2001 Sep |
|
| [Tuberculous osteitis of the malar bone]. | 2002 |
|
| Experimental study on phototoxicity and the photosensitization potential of ketoprofen, suprofen, tiaprofenic acid and benzophenone and the photocross-reactivity in guinea pigs. | 2002 Apr |
|
| Differential effects of nonsteroidal antiinflammatory drugs on the IL-1 altered expression of plasminogen activators and plasminogen activator inhibitor-1 by articular chondrocytes. | 2002 Aug |
|
| Use of the photo-micronucleus assay in Chinese hamster V79 cells to study photochemical genotoxicity. | 2002 Aug 26 |
|
| Fixed drug eruption due to tiaprofenic acid. | 2002 Dec |
|
| [Cross-reaction potentials of ketoprofen]. | 2002 May 12 |
|
| [Photocontact dermatitis due to ketoprofen and photosensitization to tetrachlorosalicylanide and to Fenticlor(R)]. | 2002 Oct |
|
| Indomethacin-induced morphologic changes in the rat urinary bladder epithelium. | 2003 Jan |
|
| Thin layer chromatographic resolution of some 2-arylpropionic acid enantiomers using L-(-)-serine, L-(-)-threonine and a mixture of L-(-)-serine and L-(-)-threonine-impregnated silica gel as stationary phases. | 2003 Jul |
|
| Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. | 2003 Jun 2 |
|
| Spectrum of cross-photosensitization in 18 consecutive patients with contact photoallergy to ketoprofen: associated photoallergies to non-benzophenone-containing molecules. | 2003 Mar |
|
| Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. | 2004 Aug 2 |
|
| The modulation of intra-articular inflammation, cartilage matrix and bone loss in mono-articular arthritis induced by heat-killed Mycobacterium tuberculosis. | 2005 |
|
| In vitro interactions of captopril with NSAID's. | 2006 Jul |
|
| Use of the yeast Saccharomyces cerevisiae as a pre-screening approach for assessment of chemical-induced phototoxicity. | 2006 Sep |
|
| Upper gastrointestinal complications associated with NSAIDs in children. | 2007 Mar-Apr |
|
| Acute NSAID-related transmural duodenitis and extensive duodenal ulceration. | 2007 Nov |
|
| Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis. | 2008 |
|
| The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. | 2008 Apr 1 |
|
| The effects of etodolac, nimesulid and naproxen sodium on the frequency of sister chromatid exchange after enclused third molars surgery. | 2008 Oct 31 |
|
| Phytalgic, a food supplement, vs placebo in patients with osteoarthritis of the knee or hip: a randomised double-blind placebo-controlled clinical trial. | 2009 |
|
| Photodegradation mechanism of nonsteroidal anti-inflammatory drugs containing thiophene moieties: suprofen and tiaprofenic acid. | 2009 Aug 13 |
|
| An exploration of the ability of tepoxalin to ameliorate the degradation of articular cartilage in a canine in vitro model. | 2009 Jul 22 |
|
| Contact dermatitis due to topical drugs. | 2009 Oct |
|
| Single dose oral tiaprofenic acid for acute postoperative pain in adults. | 2009 Oct 7 |
|
| Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs. | 2009 Sep |
|
| Hemorrhagic cystitis: A challenge to the urologist. | 2010 Apr |
|
| Enhancement of antinociception by coadministration of minocycline and a non-steroidal anti-inflammatory drug indomethacin in naïve mice and murine models of LPS-induced thermal hyperalgesia and monoarthritis. | 2010 Dec 1 |
|
| The effect of terpenes on percutaneous absorption of tiaprofenic acid gel. | 2010 Nov |
|
| Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. | 2015 Jan 5 |
Patents
Sample Use Guides
The recommended daily dose range for adults is 600 mg tiaprofen acid per day divided into 2 doses.
Route of Administration:
Oral
Human osteoarthritic cartilage was treated with therapeutic doses of tiaprofenic acid (26 micrograms/ml; 2.6 micrograms/ml) in order to test the effect of the drug on the proteoglycan metabolism (catabolism and synthesis) and chondrocyte ultrastructure. The drug suppresed the proteoglycan metabolism by 38%.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
62715-04-2
Created by
admin on Sat Dec 16 08:37:21 GMT 2023 , Edited by admin on Sat Dec 16 08:37:21 GMT 2023
|
PRIMARY | |||
|
6454459
Created by
admin on Sat Dec 16 08:37:21 GMT 2023 , Edited by admin on Sat Dec 16 08:37:21 GMT 2023
|
PRIMARY | |||
|
ZR3VFO4VD3
Created by
admin on Sat Dec 16 08:37:21 GMT 2023 , Edited by admin on Sat Dec 16 08:37:21 GMT 2023
|
PRIMARY | |||
|
DTXSID60978337
Created by
admin on Sat Dec 16 08:37:21 GMT 2023 , Edited by admin on Sat Dec 16 08:37:21 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
